Live Attenuated Vaccines Market By Type (Viral Vaccine (Varicella (Chickenpox) Vaccine, Adenovirus Oral Vaccine (Military), Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Vaccinia (Smallpox) Vaccine & Other Viral Vaccines) and Bacterial Vaccine (BCG (Tuberculosis) Vaccine, Live Cholera Vaccine & Typhoid Oral Vaccine), Vaccine Development (Live Animals, Embryonated Eggs and Tissue Culture) and End User (Clinics, Research Institute, Diagnostic Centers, Hospitals and Other End User) - Global Industry Analysis And Forecast To 2025

Published On : August 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC081245

Industry Outlook

Attenuated Vaccines is a vaccine produced for limiting the severity of pathogens, but keeping them feasible (or live). Here infections agent is used which is changed so that it becomes less severe or harmless. Live Attenuated Vaccines are referred to as the most successful and economical medication in the history of medicine. Use of Live Attenuated Vaccines is growing due to; rising funding from the government for vaccination programs, increasing number of cases related to infectious diseases, highly developed healthcare sector, rising awareness amongst the people regarding infectious diseases, rising demand for prevention of various diseases, etc. Therefore, the Live Attenuated Vaccines Market is anticipated to expand and has tremendous scope during the forecast period. The global Live Attenuated Vaccines Market anticipated to flourish in the future by growing at a significantly higher CAGR.

Market Segmentation

The global Live Attenuated Vaccines Market is based on segment, by Type the market is segmented intoViral Vaccine (Varicella (Chickenpox) Vaccine, Adenovirus Oral Vaccine (Military), Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Vaccinia (Smallpox) Vaccine & Other Viral Vaccines) and Bacterial Vaccine (BCG (Tuberculosis) Vaccine, Live Cholera Vaccine & Typhoid Oral Vaccine, by Vaccine Development the market is segmented into Live Animals, Embryonated Eggs and Tissue Culture, and by End User the market is segmented into Clinics, Research Institute, Diagnostic Centers, Hospitals and Other End User.

  • Live Attenuated Vaccines Market, By Type
  • Viral Vaccine
  • Varicella (Chickenpox) Vaccine
  • Adenovirus Oral Vaccine (Military)
  • Oral Polio Vaccine (OPV)
  • Yellow Fever Vaccine
  • Vaccinia (Smallpox) Vaccine
  • Other Viral Vaccines
  • Bacterial Vaccine
  • BCG (Tuberculosis) Vaccine
  • Live Cholera Vaccine
  • Typhoid Oral Vaccine
  • Live Attenuated Vaccines Market, By Vaccine Development
  • Live Animals
  • Embryonated Eggs
  • Tissue Culture
  • Live Attenuated Vaccines Market, By End User
  • Clinics
  • Research Institute
  • Diagnostic Centers
  • Hospitals
  • Other End User

Regional Insights

On a global front, the Live Attenuated Vaccines Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). North American region is leading the Live Attenuated Vaccines Market due to; awareness programs undertaken by the government & initiatives by the government for vaccination against various diseases.

Live Attenuated Vaccines Market, By Region

    • North America
  • U.S.
  • Canada
  • Mexico
    • Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
    • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Rest of Asia-Pacific
    • South America
  • Brazil
  • Argentina
  • Columbia
  • Rest of South America
    • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of MEA

Competitive Analysis

The leading players in the market are Serum Institute of India Pvt. Ltd., Sanofi, CSL Limited, GlaxoSmithKline plc., MedImmune LLC, Astellas Pharma Inc., Merck & Co., Emergent BioSolutions, Inc., Johnson & Johnson, Pfizer Inc., Codagenix Inc., BioDiem and Vivaldi Biosciences Inc. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.

  • Serum Institute of India Pvt. Ltd.
  • Sanofi
  • CSL Limited
  • GlaxoSmithKline plc.
  • MedImmune LLC
  • Astellas Pharma Inc.
  • Merck & Co.
  • Emergent BioSolutions, Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Codagenix Inc.
  • BioDiem
  • Vivaldi Biosciences Inc.

Some of the key questions answered by the report are:          

  • What was the market size in 2014 and forecast from 2015 to 2025?
  • What will be the industry market growth from 2015 to 2025?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

o   Live Attenuated Vaccines Market, By Type, Estimates and Forecast, 2014-2025 ($Million)

o   Viral Vaccine

§  Varicella (Chickenpox) Vaccine

§  Adenovirus Oral Vaccine (Military)

§  Oral Polio Vaccine (OPV)

§  Yellow Fever Vaccine

§  Vaccinia (Smallpox) Vaccine

§  Other Viral Vaccines

o   Bacterial Vaccine

§  BCG (Tuberculosis) Vaccine

§  Live Cholera Vaccine

§  Typhoid Oral Vaccine

o   Live Attenuated Vaccines Market, By Vaccine Development, Estimates and Forecast, 2014-2025 ($Million)

o   Live Animals

o   Embryonated Eggs

o   Tissue Culture

o   Live Attenuated Vaccines Market, By End Users, Estimates and Forecast, 2014-2025 ($Million)

o   Clinics

o   Research Institute

o   Diagnostic Centers

o   Hospitals

o   Other End User

Live Attenuated Vaccines Market, By Region, Estimates and Forecast, 2014-2025 ($Million)

o   North America

§  North America Live Attenuated Vaccines Market, By Country

o   U.S. Live Attenuated Vaccines Market

o   Canada Live Attenuated Vaccines Market

o   Mexico Live Attenuated Vaccines Market

o   Europe

§  Europe Live Attenuated Vaccines Market, By Country

o   Germany Live Attenuated Vaccines Market

o   UK Live Attenuated Vaccines Market

o   France Live Attenuated Vaccines Market

o   Russia Live Attenuated Vaccines Market

o   Italy Live Attenuated Vaccines Market

o   Rest of Europe Live Attenuated Vaccines Market

o   Asia-Pacific

§  Asia-Pacific Live Attenuated Vaccines Market, By Country

o   China Live Attenuated Vaccines Market

o   Japan Live Attenuated Vaccines Market

o   South Korea  Live Attenuated Vaccines Market

o   India Live Attenuated Vaccines Market

o   Southeast Asia Live Attenuated Vaccines Market

o   Rest of Asia-Pacific Live Attenuated Vaccines Market

o   South America

§  South America Live Attenuated Vaccines Market, By Country

o   Brazil Live Attenuated Vaccines Market

o   Argentina Live Attenuated Vaccines Market

o   Columbia Live Attenuated Vaccines Market

o   Rest of South America Live Attenuated Vaccines Market

o   Middle East and Africa

§  Middle East and Africa Live Attenuated Vaccines Market, By Country

o   Saudi Arabia Live Attenuated Vaccines Market

o   UAE Live Attenuated Vaccines Market

o   Egypt Live Attenuated Vaccines Market

o   Nigeria Live Attenuated Vaccines Market

o   South Africa Live Attenuated Vaccines Market

o   Rest of MEA Live Attenuated Vaccines Market

Table of Contents

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2014-2025)

4.1.2.  Canada Market Status and Outlook (2014-2025)

4.1.3.  Mexico Market Status and Outlook (2014-2025)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2014-2025)

4.2.2.  France Market Status and Outlook (2014-2025)

4.2.3.  UK Market Status and Outlook (2014-2025)

4.2.4.  Russia Market Status and Outlook (2014-2025)

4.2.5.  Italy Market Status and Outlook (2014-2025)

4.2.6.  Rest of Europe Market Status and Outlook (2014-2025)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2014-2025)

4.3.2.  Japan Market Status and Outlook (2014-2025)

4.3.3.  Korea Market Status and Outlook (2014-2025)

4.3.4.  India Market Status and Outlook (2014-2025)

4.3.5.  Southeast Asia Market Status and Outlook (2014-2025)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2014-2025)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2014-2025)

4.4.2.  Argentina Market Status and Outlook (2014-2025)

4.4.3.  Columbia Market Status and Outlook (2014-2025)

4.4.4.  Rest of South America Market Status and Outlook (2014-2025)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2014-2025)

4.5.2.  United Arab Emirates Market Status and Outlook (2014-2025)

4.5.3.  Egypt Market Status and Outlook (2014-2025)

4.5.4.  Nigeria Market Status and Outlook (2014-2025)

4.5.5.  South Africa Market Status and Outlook (2014-2025)

4.5.6.  Turkey Market Status and Outlook (2014-2025)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2014-2025)

5.       Live Attenuated Vaccines Market, By Type

5.1.     Introduction

5.2.     Global Live Attenuated Vaccines Revenue and Market Share by Type (2014-2018)

5.2.1.  Global Live Attenuated Vaccines Revenue and Revenue Share by Type (2014-2018)

5.3.     Viral Vaccine

5.3.1.  Global Viral Vaccine Revenue and Growth Rate (2014-2018)

5.3.2.  Global Viral Vaccine By Type (2014-2018)

5.3.3.  Varicella (Chickenpox) Vaccine

5.3.3.1.  Global Varicella (Chickenpox) Vaccine  Revenue and Growth Rate (2014-2018)

5.3.4.  Adenovirus Oral Vaccine (Military)

5.3.4.1.  Global Adenovirus Oral Vaccine (Military)  Revenue and Growth Rate (2014-2018)

5.3.5.  Oral Polio Vaccine (OPV)

5.3.5.1.  Global Oral Polio Vaccine (OPV) Revenue and Growth Rate (2014-2018)

5.3.6.  Yellow Fever Vaccine

5.3.6.1.  Global Yellow Fever Vaccine  Revenue and Growth Rate (2014-2018)

5.3.7.  Vaccinia (Smallpox) Vaccine

5.3.7.1.  Global Vaccinia (Smallpox) Vaccine Revenue and Growth Rate (2014-2018)

5.3.8.  Other Viral Vaccines

5.3.8.1.  Global Other Viral Vaccines Revenue and Growth Rate (2014-2018)

5.4.     Bacterial Vaccine

5.4.1.  Global Bacterial Vaccine Revenue and Growth Rate (2014-2018)

5.4.2.  Global Bacterial Vaccine By Type (2014-2018)

5.4.3.  BCG (Tuberculosis) Vaccine

5.4.3.1.  Global BCG (Tuberculosis) Vaccine Revenue and Growth Rate (2014-2018)

5.4.4.  Live Cholera Vaccine

5.4.4.1.  Global Live Cholera Vaccine  Revenue and Growth Rate (2014-2018)

5.4.5.  Typhoid Oral Vaccine

5.4.5.1.  Global Typhoid Oral Vaccine  Revenue and Growth Rate (2014-2018)

6.       Live Attenuated Vaccines Market, By Vaccine Development

6.1.     Introduction

6.2.     Global Live Attenuated Vaccines Revenue and Market Share by Vaccine Development (2014-2018)

6.2.1.  Global Live Attenuated Vaccines Revenue and Revenue Share by Vaccine Development (2014-2018)

6.3.     Live Animals

6.3.1.  Global Live Animals Revenue and Growth Rate (2014-2018)

6.4.     Embryonated Eggs

6.4.1.  Global Embryonated Eggs  Revenue and Growth Rate (2014-2018)

6.5.     Tissue Culture

6.5.1.  Global Tissue Culture Revenue and Growth Rate (2014-2018)

7.       Live Attenuated Vaccines Market, By End User

7.1.     Introduction

7.2.     Global Live Attenuated Vaccines Revenue and Market Share by End User (2014-2018)

7.2.1.  Global Live Attenuated Vaccines Revenue and Revenue Share by End User (2014-2018)

7.3.     Clinics

7.3.1.  Global Clinics  Revenue and Growth Rate (2014-2018)

7.4.     Research Institute

7.4.1.  Global Research Institute Revenue and Growth Rate (2014-2018)

7.5.     Diagnostic Centers

7.5.1.  Global Diagnostic Centers  Revenue and Growth Rate (2014-2018)

7.6.     Hospitals

7.6.1.  Global Hospitals Revenue and Growth Rate (2014-2018)

7.7.     Other End User

7.7.1.  Global Other End User Revenue and Growth Rate (2014-2018)

8.       Live Attenuated Vaccines Market, By Region

8.1.     Introduction

8.2.     Global Live Attenuated Vaccines Revenue and Market Share by Regions

8.2.1.  Global Live Attenuated Vaccines Revenue by Regions (2014-2018)

8.3.     North America Live Attenuated Vaccines by Countries

8.3.1.  North America Live Attenuated Vaccines Revenue and Growth Rate (2014-2018)

8.3.2.  North America Live Attenuated Vaccines Revenue (Million USD) by Countries (2014-2018)

8.3.3.  United States

8.3.3.1.  United States Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.3.4.  Canada

8.3.4.1.  Canada Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.3.5.  Mexico

8.3.5.1.  Mexico Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.     Europe Live Attenuated Vaccines by Countries

8.4.1.  Europe Live Attenuated Vaccines Revenue and Growth Rate (2014-2018)

8.4.2.  Europe Live Attenuated Vaccines Revenue (Million USD) by Countries (2014-2018)

8.4.3.  Germany

8.4.3.1.  Germany Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.4.  France

8.4.4.1.  France Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.5.  UK

8.4.5.1.  UK Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.6.  Russia

8.4.6.1.  Russia Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.7.  Italy

8.4.7.1.  Italy Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.8.  Rest of Europe

8.4.8.1.  Rest of Europe Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.     Asia-Pacific Live Attenuated Vaccines by Countries

8.5.1.  Asia-Pacific Live Attenuated Vaccines Revenue and Growth Rate (2014-2018)

8.5.2.  Asia-Pacific Live Attenuated Vaccines Revenue (Million USD) by Countries (2014-2018)

8.5.3.  China

8.5.3.1.  China Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.4.  Japan

8.5.4.1.  Japan Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.5.  Korea

8.5.5.1.  Korea Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.6.  India

8.5.6.1.  India Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.7.  Southeast Asia

8.5.7.1.  Southeast Asia Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.8.  Rest of Asia-Pacific

8.5.8.1.  Rest of Asia-Pacific Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.     South America Live Attenuated Vaccines by Countries

8.6.1.  South America Live Attenuated Vaccines Revenue and Growth Rate (2014-2018)

8.6.2.  South America Live Attenuated Vaccines Revenue (Million USD) by Countries (2014-2018)

8.6.3.  Brazil

8.6.3.1.  Brazil Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.4.  Argentina

8.6.4.1.  Argentina Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.5.  Columbia

8.6.5.1.  Columbia Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.6.  Rest of South America

8.6.6.1.  Rest of South America Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.     Middle East and Africa Live Attenuated Vaccines by Countries

8.7.1.  Middle East and Africa Live Attenuated Vaccines Revenue and Growth Rate (2014-2018)

8.7.2.  Middle East and Africa Live Attenuated Vaccines Revenue (Million USD) by Countries (2014-2018)

8.7.3.  Saudi Arabia

8.7.3.1.  Saudi Arabia Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.4.  United Arab Emirates

8.7.4.1.  United Arab Emirates Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.5.  Egypt

8.7.5.1.  Egypt Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.6.  Nigeria

8.7.6.1.  Nigeria Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.7.  South Africa

8.7.7.1.  South Africa Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.8.  Turkey

8.7.8.1.  Turkey Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.9.  Rest of Middle East and Africa

8.7.9.1.  Rest of Middle East and Africa Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2014-2018)

9.       Company Profiles

9.1.     Serum Institute of India Pvt. Ltd.

9.1.1.  Business Overview

9.1.2.   Service Portfolio

9.1.3.  Strategic Developments

9.1.4.   Revenue and Market Share

9.2.     Sanofi

9.2.1.  Business Overview

9.2.2.   Service Portfolio

9.2.3.  Strategic Developments

9.2.4.   Revenue and Market Share

9.3.     CSL Limited

9.3.1.  Business Overview

9.3.2.   Service Portfolio

9.3.3.  Strategic Developments

9.3.4.   Revenue and Market Share

9.4.     GlaxoSmithKline plc.

9.4.1.  Business Overview

9.4.2.   Service Portfolio

9.4.3.  Strategic Developments

9.4.4.   Revenue and Market Share

9.5.     MedImmune LLC

9.5.1.  Business Overview

9.5.2.   Service Portfolio

9.5.3.  Strategic Developments

9.5.4.   Revenue and Market Share

9.6.     Astellas Pharma Inc.

9.6.1.  Business Overview

9.6.2.   Service Portfolio

9.6.3.  Strategic Developments

9.6.4.   Revenue and Market Share

9.7.     Merck & Co.

9.7.1.  Business Overview

9.7.2.   Service Portfolio

9.7.3.  Strategic Developments

9.7.4.   Revenue and Market Share

9.8.     Emergent BioSolutions, Inc.

9.8.1.  Business Overview

9.8.2.   Service Portfolio

9.8.3.  Strategic Developments

9.8.4.   Revenue and Market Share

9.9.     Johnson & Johnson

9.9.1.  Business Overview

9.9.2.   Service Portfolio

9.9.3.  Strategic Developments

9.9.4.   Revenue and Market Share

9.10. Pfizer Inc.

9.10.1.      Business Overview

9.10.2.       Service Portfolio

9.10.3.      Strategic Developments

9.10.4.       Revenue and Market Share

9.11. Codagenix Inc.

9.11.1.      Business Overview

9.11.2.       Service Portfolio

9.11.3.      Strategic Developments

9.11.4.       Revenue and Market Share

9.12. BioDiem

9.12.1.      Business Overview

9.12.2.       Service Portfolio

9.12.3.      Strategic Developments

9.12.4.       Revenue and Market Share

9.13. Vivaldi Biosciences Inc.

9.13.1.      Business Overview

9.13.2.       Service Portfolio

9.13.3.      Strategic Developments

9.13.4.       Revenue and Market Share

10.    Global Live Attenuated Vaccines Market Competition, by Manufacturer

10.1. Global Live Attenuated Vaccines Revenue and Market Share by Manufacturer (2016-2017)

10.2. Global Live Attenuated Vaccines Price By Region (2016-2017)

10.3. Top 5 Live Attenuated Vaccines Manufacturer Market Share

10.4. Market Competition Trend

11.    Live Attenuated Vaccines Market Forecast (2018-2025)

11.1. Global Live Attenuated Vaccines Revenue (Millions USD) and Growth Rate (2018-2025)

11.2. Live Attenuated Vaccines Market Forecast by Regions (2018-2025)

11.2.1.      North America Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.1.1. United States Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.1.2. Canada Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.1.3. Mexico Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.2.      Europe Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.2.1. Germany Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.2.2. France Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.2.3. UK Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.2.4. Russia Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.2.5. Italy Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.2.6. Rest of Europe Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.3.      Asia-Pacific Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.3.1. China Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.3.2. Japan Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.3.3. Korea Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.3.4. India Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.3.5. Southeast Asia Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.3.6. Rest of Asia-Pacific Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.4.      South America Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.4.1. Brazil Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.4.2. Argentina Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.4.3. Columbia Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.4.4. Rest of South America Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.5.      Middle East and Africa Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.5.1. Saudi Arabia Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.5.2. United Arab Emirates Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.5.3. Egypt Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.5.4. Nigeria Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.5.5. South Africa Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.5.6. Turkey Live Attenuated Vaccines Market Forecast (2018-2025)

11.2.5.7. Rest of Middle East and Africa Live Attenuated Vaccines Market Forecast (2018-2025)

11.3. Live Attenuated Vaccines Market Forecast by Type (2018-2025)

11.3.1.      Live Attenuated Vaccines Forecast by Type (2018-2025)

11.3.2.      Live Attenuated Vaccines Market Share Forecast by Type (2018-2025)

11.4. Live Attenuated Vaccines Market Forecast by Vaccine Development (2018-2025)

11.4.1.      Live Attenuated Vaccines Forecast by Vaccine Development (2018-2025)

11.4.2.      Live Attenuated Vaccines Market Share Forecast by Vaccine Development (2018-2025)

11.5. Live Attenuated Vaccines Market Forecast by End User (2018-2025)

11.5.1.      Live Attenuated Vaccines Forecast by End User (2018-2025)

Live Attenuated Vaccines Market Share Forecast by End User (2018-2025)


List of Tables

12. List of Tables and Figures
Figure United States Live Attenuated Vaccines Revenue (Million USD) and Growth Rate (2014-2025)
Figure Canada Live Attenuated Vaccines Revenue (Million USD) and Growth Rate (2014-2025)
Figure Mexico Live Attenuated Vaccines Revenue (Million USD) and Growth Rate (2014-2025)
Figure Germany Live Attenuated Vaccines Revenue (Million USD) and Growth Rate (2014-2025)
Figure France Live Attenuated Vaccines Revenue (Million USD) and Growth Rate (2014-2025)
Figure UK Live Attenuated Vaccines Revenue (Million USD) and Growth Rate (2014-2025)
Figure Russia Live Attenuated Vaccines Revenue (Million USD) and Growth Rate (2014-2025)
Figure Italy Live Attenuated


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*